Abstract: Fecal microbiota transplantation (FMT) has changed the standard of care for Clostridium difficile infection. However, there is limited data focusing on efficacy and safety profile of FMT in patients with C. difficile infection with underlying inflammatory bowel disease (IBD), including the risk of IBD flare. Recently, there is also emerging evidence supporting the role of FMT to treat IBD including promising randomized trials in ulcerative colitis. However, with heterogeneity across these studies, the clinical application of this emerging therapy has yet to be fully elucidated. Here, we aim to review the current landscape of this rapidly developing field, mapping the efficacy and safety of FMT (1) to treat C. difficile infection in patients with IBD, (2) to treat underlying IBD, and (3) outline ongoing clinical trials and the future of the microbiome space.
F ecal microbiota transplantation (FMT) has changed the standard of care for Clostridium difficile infection (CDI). Four randomized clinical trials and a number of meta-analyses suggest a nearly 90% cure rate of FMT for the treatment of recurrent CDI with a tolerable safety profile. 1 However, there is limited data focusing on efficacy and safety profile of FMT in patients with CDI with inflammatory bowel disease (IBD), including the risk of IBD flare. Recently, there is also emerging evidence supporting the role of FMT to treat underlying IBD, [2] [3] [4] including promising randomized trials in ulcerative colitis (UC). However, with heterogeneity across these trials, the clinical application of this emerging therapy has yet to be fully elucidated. Overall, the role of FMT in IBD both with and without CDI is crucial for clinicians. Here, we aim to review the current landscape of this rapidly developing field, mapping the efficacy and safety of FMT (1) to treat CDI in patients with IBD, (2) to treat underlying IBD and (3) outline ongoing clinical trials and the future of the microbiome space.
METHODS
An electronic search was conducted using MEDLINE (1950-May 2017), EMBASE (1947-December 2017), Cochrane Central Register of Controlled Trials (2017) and ClinicalTrials. gov. Search terms included alternatives of FMT combined with varied terms of IBD but not limited to Crohn's disease (CD), UC, and IBD. Discussion with content experts was conducted to obtain key references. Furthermore, a recursive search of the bibliographies of all relevant articles was completed.
RESULTS

Fecal Microbiota Transplantation for the Treatment of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease: The Current Landscape
Over the last decade, there has been an increase in the incidence and severity of CDI that has been attributed to more virulent and treatment refractory strains 5, 6 ; and its impact has been especially pernicious in patients with IBD. [7] [8] [9] The prevalence of CDI in the IBD population was reported to be 2.5-to 8-fold higher than otherwise matched controls with a 10% lifetime risk of contracting the pathogen. [10] [11] [12] [13] After an initial course of anti-CDI therapy, the CDI recurrence rate is 4.5-fold higher, and the prevalence of toxigenic C. difficile carrier state is 8-fold greater in patients with IBD compared with non-IBD patients. 14 Nevertheless, patients with IBD with CDI tend to improve on standard of care anti-CDI antibiotics, suggesting that prompt treatment of CDI may prevent colectomy. Although FMT is routinely used to treat recurrent CDI in patients with IBD, there is limited data for its role in this patient population. Kelly and colleagues demonstrated an overall cure rate of 94% in immunosuppressed patients but reported a 14% IBD exacerbation rate, which includes both de novo flares of IBD and disease decompensation after FMT, raising concern about possible deleterious effects of FMT in patients with IBD with patients with CDI. 15 To date, there have been several small studies assessing the effect of FMT for CDI in patients with IBD, but here we will focus on the 3 largest studies.
The first prospective study, presented as a brief report, comes from Khalili et al. 16 Patients with recurrent CDI (2 or more episodes) and IBD were included. Thirty-five patients were enrolled (22 UC and 13 CD). Most patients in this study received FMT via oral capsule (n ¼ 27). Post-FMT, 13 patients underwent additional testing for CDI and only 1 was positive. Regarding IBD, more than half of the patients (n ¼ 19) required IBD treatment escalation with glucocorticoids (n ¼ 5), anti-TNF therapy (n ¼ 7), or vedolizumab (n ¼ 3). Two patients required surgery. It was noted that patients with inactive IBD at the time of FMT (n ¼ 22) generally did not require treatment escalation (64%).
The second study was performed at the University of Minnesota and included patients with preexisting IBD or IBD diagnosed at the time of FMT. 17 Endoscopic disease activity assessments were performed during the FMT. Patients were included if they failed an extended course of standard of care anti-CDI antibiotics. All FMTs were performed by colonoscopy using the institution's standard universal donor program. They enrolled 56 patients (28 UC and 28 CD) including 7 patients who had their IBD diagnosed at the time of FMT. Overall, they report a single FMT was successful at eradicating CDI in 85.7% of patients. However, more than half of the patients with UC experienced a flare of their disease. Notably, those with severe disease at the time of endoscopy were much more likely to experience a flare. More than 1 FMT was required in 14.3% of patients. Interestingly, they found that 23% of patients experienced a "late failure" (3-12 mo post-FMT) after being confirmed as negative by stool testing at the 2-month post-FMT visit although it's unclear if this was reinfection.
Last, Fischer et al 18 conducted a multicenter, retrospective cohort study assessing patients who underwent FMT for recurrent or refractory CDI with concurrent IBD. All FMTs were performed by colonoscopy or sigmoidoscopy. Overall, 67 patients were enrolled at 8 institutions (35 CD, 31 UC, and 1 indeterminate colitis). At the time of FMT, 64% of patients were on an immunosuppressive agent. In addition, at the time of FMT, 39 (58%) patients were considered to have clinically active IBD and 76% had endoscopically active disease. After a single FMT, 79% of patients experienced clinical cure from their CDI. After a second FMT, the cumulative success rate was 90%. Regarding IBD prognosis, the overall clinical course at 3 months post-FMT was found to be unchanged in 35.8% of patients, improved in 46.3% and worse in 17.9%. In a subset of patients, disease activity scores pre-and post-FMT were collected. Harvey Bradshaw indices collected in patients with CD (n ¼ 23) decreased from a median of 7 to 2 post-FMT (P ¼ 0.004). The equivalent was not found in patients with UC (n ¼ 7) measured by UC clinical score (UCCS). In addition, predictors of FMT failure among this cohort were assessed and the authors report inpatient status and low serum albumin at the time of FMT were associated with likelihood to fail FMT. 
Fecal
Disease Activity
Clinicians must be aware of the patient's underlying IBD activity at the time of FMT. As observed across these studies, patients with IBD with more severe disease at the time of FMT are more likely to have flares or need increased IBD therapy post-FMT. Thus, conducting both a clinical and endoscopic assessment at the time of FMT may be critical; clinicians should leverage this information in the informed consent process and apply it in post-FMT care to guide monitoring.
Symptom Etiology-Differentiating Between CDI and Active IBD
Patients with IBD often have baseline diarrheal symptoms and may continue to have diarrhea post-FMT, thus understanding the etiology of diarrhea is key to providing appropriate medical therapy. Accordingly, using C. difficile toxin A/B enzyme immunoassay testing for toxin to confirm CDI instead of PCR for the C. difficile toxin gene is clinically useful in this patient population. PCR testing may identify patients who are colonized with C. difficile but may not have true underlying infection. Colonization may be a marker of IBD severity, and so determining true infection is important. Accordingly, we recommend clinicians follow the 2016 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for CDI testing, which state that no single commercial test should be used as a stand-alone test for diagnosing CDI and recommend a 2-step approach (highly sensitive with reflex to highly specific test). 19 These guidelines recommend performing an initial test with a high negative predictive value, therefore if negative, no further testing needs to be performed. Specifically, they suggest glutamate dehydrogenase (GDH) enzyme immunoassay or PCR testing. The second test should be a test with a high positive predictive value, such as enzyme immunoassay for toxin A/B. Understanding if true infection exists will help guide clinicians to determining if a second FMT or escalation of medical therapy for IBD is needed.
Mode of Administration
Before FMT administration, clinicians should conduct a comprehensive mucosal assessment, preferably with documentation of an endoscopic disease activity score thereby allowing for a more objective comparison in the future, should the patient develop an IBD flare postprocedure. Accordingly, FMT by colonoscopic administration may be the most useful delivery modality for FMT in patients with IBD. In addition, as patients with IBD have poorer CDI outcomes, including mortality, compared with non-IBD patients, 10, 20 and FMT by colonoscopic administration seems more effective than upper GI administration and current capsules 21, 22 ; FMT by colonoscopy may be the ideal delivery modality for patients with IBD for the treatment of CDI.
Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: The Current Landscape
The exact etiology of IBD is unclear, however, the role of gut microbiota in the etiopathogenesis continues to evolve. Specifically, patients with IBD have demonstrated significant microbial dysbiosis, characterized by decreased overall alpha diversity, and a decrease in Bacteriodetes and Firmicutes as well as a decreased abundance of Faecalibacterium prausnitzii. 3 Accordingly, an altered gut microbiota has been proposed as a key contributing factor for the pathogenesis of gut inflammation in IBD. 4, 5 This association is supported by animal models, demonstrating that transfer of microbiota from diseased to healthy mice is sufficient to induce intestinal inflammation. [6] [7] [8] Accordingly, manipulating the microbiome through FMT, has been explored as a novel therapeutic treatment for IBD.
The evidence for FMT as a treatment of CD is currently more limited compared with UC, and therefore the role of FMT in treating CD remains uncertain. In addition, CD is a more heterogeneous disease, thus it may be necessary to study unique disease phenotypes as opposed to more general populations. Nonetheless, several promising clinical trials are currently underway, which may provide insight if positive outcomes observed in small cohorts can be replicated in a larger population. Given this context, we will focus on FMT for the treatment of active UC.
To date, 4 randomized controlled trials have examined FMT for patients with UC, with promising results (Table 1) . Together, these studies suggest that FMT may be effective in inducing remission of active UC. 23, 24 Moayyedi et al conducted the first randomized controlled trial (n ¼ 75), which included patients with active UC (defined as a Mayo Clinic score of greater or equal to 4). Concomitant medications that were permitted include oral mesalamine, glucocorticoids, azathioprine, and anti-TNF agents, provided they have been stable for 12 weeks (4 weeks for steroids). Patients were randomized to either treatment with FMT from a healthy donor (50 mL via enema) once per week for 6 weeks or placebo, which consisted of a water enema administered at the same cadence and volume. 2 The primary endpoint assessed was induction of UC remission, defined as complete Mayo score ,3 and endoscopic Mayo subscore ¼ 0 at week 7. In the FMT arm, 9/38 (24%) patients achieved remission, versus only 2/37 (5%) in control arm (P ¼ 0.03). Importantly, 7/9 (78%) patients who achieved remission were treated with stool from a single donor, Donor B. A comparison of the microbiota composition in responders and nonresponders treated with Donor B showed a trend toward greater similarity of gut microbiota in responders to that of Donor B.
Although having a small sample size, this landmark study highlighted the importance of careful donor selection in the trial design process in the setting of UC. The second randomized controlled trial (n ¼ 50) by Rossen et al examined patients with mild to moderately active UC (defined as an Simple Clinical Colitis Index (SCCAI) $4 and # 11). Concomitant medications that were permitted include thiopurines, mesalamine, and corticosteroids at stable for 8 weeks before inclusion. Unlike Moayyedi et al, patients were excluded if they used anti-TNF within 8 weeks before screening. Patients were randomized to receive either 2 nasoduodenal infusions of fresh donor stool (week 0 and week 3) or 2 infusions using autologous fecal material. 3 Rossen et al found no statistically significant effect of FMT on the primary endpoint (composite score of clinical remission, defined as a SCCAI score #2 and $1-point improvement in Mayo endoscopic subscore) at week 12, although did report a directional change. Specifically, in the intention to treat population they found that 7/23 (30%) patients went into remission in the FMT arm versus 5/25 (20%) in the placebo arm (P ¼ 0.29). The authors did note that the microbial profile of responders shifted to resemble that of donors at follow-up. 25 Furthermore, microbial analysis demonstrated distinct differences in microbiota at week 12 between sustained responders and patients who relapsed at 1 year. The microbiota of sustained responders were enriched for short chain fatty acid producing bacteria, providing a possible basis for donor selection in future studies. Adverse events were similar in both groups. One patient developed a CMV infection; however, this patient was in the autologous control arm.
The third trial, FOCUS, was a multicenter, randomized placebo-controlled trial of FMT to treat mild to moderate UC (defined as a clinical Mayo score 4-10 and an endoscopic subscore greater or equal to 1). 4 The concomitant medications that were permitted include oral mesalamine, thiopurines and methotrexate, and oral prednisone 20 mg or less with a fixed taper of 2.5-mg a week during the study. Similar to Rosen et al, patients were excluded if they received anti-TNFs within 12 weeks before screening. Patients were randomized to either the treatment arm (n ¼ 41) and underwent an induction FMT by colonoscopy, followed by FMT enemas 5 days per week for 8 weeks, or randomized to the control arm (n ¼ 40) and received placebo FMT by colonoscopy, followed by placebo enemas at the same cadence as the treatment arm. Importantly, each fecal microbiota preparation contained material from 3 to 7 unrelated donors. FMT had a statistically significant effect on achieving the primary, composite endpoint of steroid-free clinical remission and endoscopic remission or response at 8 weeks. This was defined as a total Mayo score #2 with all 4 subscores #1 and $ point reduction in endoscopic subscore. In the FMT group, 11/41 (27%) achieved the outcome compared with 3/40, (8%) in the placebo arm (P ¼0.021). Patients in the control group who entered into the 8-week open-label extension arm were also able to achieve the primary endpoint (27%, 10/37), supporting the initial findings. Similarly to the Moayyedi trial, 1 donor (Donor 54) was associated with more benefit than other donors, alhough the study was not powered to assess donor effect.
More recently, Costello et al, 26 presented the fourth randomized, placebo-controlled trial. This trial included mildmoderate active patients with UC (defined as l Mayo score of 3-10 and an endoscopic Mayo subscore of 2 or greater). In addition, stable maintenance medications that were permitted include oral and rectal mesalamine, thiopurines, methotrexate, infliximab, or vedolizumab. Patients on prednisolone (20 mg or less) were put on a mandatory taper. The intervention arm received stool from 3 to 4 healthy donors and the material was prepared anaerobically, which differentiates this study from its predecessors. Anaerobically, prepared material may potentially help retain microbes that would otherwise not be viable with traditional aerobically prepared FMT. The placebo group received autologous FMT. Patients received an initial treatment through colonoscopy followed by 2 enemas at week 1, in a lowintensity FMT approach. The primary endpoint was steroid-free remission of UC at week 8, defined as a total Mayo score ,2 and a Mayo endoscopic subscore of ,1. Outcomes were assessed at week 8. The treatment arm reached the primary endpoint in 32% of patients (12/38) compared with 9% (3/35) in the placebo arm (P ¼ 0.02).
Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: Lessons to Consider
The role of FMT in active UC is still emerging and further studies are needed to untangle the heterogeneity embedded in the 4 randomized controlled trials. However, 3 research lessons should be considered for future trials in this space.
Donor Selection
Unlike in CDI 27 in which data suggest that there is no donor profile that impacts efficacy, FMT studies in UC studies suggest that there may be a "super donor" phenomenon. Moayyedi et al reported material from Donor B-induced remission in 39% of active UC patients compared with 10% among material from non-Donor B sources. Similarly, Paramsothy et al reported among patients with UC who received batches that included Donor 54 (n ¼ 38), 37% achieved the primary outcome, compared with patients who received batches that did not include Donor 54 (n ¼ 40) only 18% achieved the primary outcome (P ¼ 0.054). Although both studies were not powered to detect a donor effect, the results serve as an important lesson. While the microbial characteristics of the "super donor" for UC is still unknown, it raises the question whether clinical scientists should make a more rational donor selection for IBD studies as has been demonstrated in a recent FMT randomized clinical trial for hepatic encephalopathy. 28 Potential donor qualities that can be considered include, but are not limited to, an increase in overall diversity or microbes that are depleted in patients with IBD.
Mode of Administration and Dosing Frequency
The ideal mode of delivery may be important in IBD and may explain the low efficacy rate observed by Rossen et al, which study used a nasodudeonal approach as compared to lower GI delivery in the other 3 positive trials.
Interestingly, nasoduodenal administration has been shown to be less efficacious for the treatment of recurrent C. difficile 1,29 compared with lower GI delivery. 30 In addition, FMT dosing frequency may have an impact in IBD. Whereas the Rossen et al trial only had 2 doses, the other studies used significantly more fecal infusions, which may be necessary to treat active inflammation, although Costello et al did only use 3 infusions.
Stool Preparation
The trial by Costello et al was the first to use anaerobically prepared fecal material. Although the efficacy results were in keeping with studies by Moayyedi et al and Paramsothy et al, it is unclear if this method of preparation may have enabled a lower intensity treatment interval. Further trials and deeper microbial characterization such as PMA-sequencing are needed to ascertain whether anaerobic preparation preserves important microbial communities that drive remission. 31 While these trials affirm that FMT is a promising induction treatment in active UC, the heterogeneity among these results highlight the need for critical examination of patient characteristics, donor factors, intervention modality and frequency, and clinical endpoints in future study design as well as longer endpoints to understand the role of FMT as maintenance therapy. (Table 2 ). Our group is currently enrolling a trial (NCT03106844) aimed at assessing the efficacy of FMT in CDI in adult patients with underlying IBD and will be following IBD clinical outcomes post-FMT. A similar trial in pediatric patients with IBD with CDI is also enrolling. Both trials are delivering FMT via colonoscopy from a universal stool bank.
Future of the Field: Active Clinical Trials for the Use of FMT in IBD
Currently, 27 actively enrolling clinical trials were found to use FMT for IBD on www.clinicaltrials.gov (June 1, 2017) . Overall, 14 studies for UC in various stages of enrollment with a number of different designs (Table 3) , 5 studies for CD (Table 4) and an additional 8 studies examining both UC and CD within 1 study. Interestingly, only 6/14 (42%) of publicly reported studies in UC are being conducted in the United States, affirming that there is global interest in FMT as a treatment for IBD. Results from these studies are likely to yield additional insight into the suitability of FMT for treatment of UC, although generalizability will be limited by small sample sizes and heterogeneity between and within studies.
While results from published case and cohort studies suggest that there is potential for FMT to treat CD, further research is needed to draw conclusions about the utility of FMT for this patient population and subsequently which CD phenotypes are most likely to benefit. There are currently 5 active trials of FMT in CD (Table 4) . One focuses specifically on pediatric patients, a population that has previously demonstrated high response rates. 32 
Lessons for Future Studies
Accumulating evidence suggests that FMT is a promising treatment for CDI among patients with IBD and for underlying IBD. Results from recent randomized controlled trials suggest a potential role for FMT in inducing remission in active UC. However, outcomes of FMT vary dramatically between patients, and between studies, because of heterogeneity within the patient population, intervention, and outcomes measured. Therefore, further research is needed to explore key features of study design including informed donor selection, patient population and disease phenotype (especially among patients with CD where there is higher disease heterogeneity), delivery modality, administration of pretreatment antibiotics and delivery frequency. Such work can help to optimize the efficacy of FMT and provide the foundation for developing microbiomebased therapies consisting of rationally selected microbial consortiums. Significant refinements in trial design and treatment protocol may yield greater clarity into the efficacy and underlying mechanisms of FMT for the treatment of IBD as well as how to increase the efficacy of FMT for the treatment of CDI in IBD. 33 Future investigators should carefully consider patient population, intervention design, and outcome measures. We will now focus on specific recommendations for future trials in IBD.
Patient Population
There is currently insufficient data to draw strong conclusions regarding which IBD phenotypes will benefit the most from FMT. The results from the Moayyedi et al suggest that FMT may be more effective earlier in the course of disease and patients with mild UC. 2, 34 This raises the question, would microbial therapies earlier in the treatment paradigm, including at diagnosis or among patients with mild disease be more effective. 33 In addition, given the safety profile of microbial therapies, treatment to prevent the development of IBD among high risk individuals may be an area of research worth exploring although should be approached with caution. Although Moayyedi et al included patients with severe UC, it is unclear whether there is a role for FMT in severe medically refractory active UC. FMT may be less likely to moduldate severe disease with significantly damaged colonocytes and may have an increased risk of adverse events with lumenal bacterial translocation leading to bacteremias, although further research is required.
Intervention
The existing trials use multiple treatments (induction dose and maintenance dosing), suggesting that multiple treatments may be necessary to achieve remission in IBD. While treatment of CDI generally requires a single treatment for most patients, results from a number of studies reveal that efficacy improves with multiple FMTs, particularly in patients with severe and severe-complicated CDI (Fischer et al: 62% initial cure rate versus 93% overall cure rate). [35] [36] [37] For the treatment of IBD, maintenance therapy will likely be needed to induce lasting remission, similar to other therapies used in IBD. Trials that use a multitreatment method may require less invasive administration modalities (e.g., capsules) to reduce risk and enhance patient adherence. Overall, the most effective dose and interval remain unknown and may be different for different IBD populations. 33 Donor selection remains an important issue as preliminary evidence suggests that clinical outcomes in UC may be dependent on a donor's microbiome profile. To understand which donor characteristics associate with remission, we suggest deep molecular characterization of the donor microbiota before treatment. This may help guiding rational donor in the design phase or retrospectively used to identify "super donor" signatures when combined with pre-and post-samples from a recipient. Aggregating stool from multiple donors, either across a treatment course or within a single FMT dose, as was used in the positive FOCUS trial, is another consideration although safety considerations linked to traceability become more challenging for pooling of multiple donors. 2, 4, 33 Last, pretreatment with either antibiotics or bowel lavage to facilitate microbial engraftment should also be considered. Pretreatment with antibiotics has been used with positive outcomes in both UC and CD. 38, 39 One may potentially extrapolate from the literature in recurrent CDI, in which FMT is often performed when the recipient has a relatively low alpha diversity because of the need for ongoing antibiotic treatment for C. difficile. This low alpha diversity may facilitate engraftment of 'healthy' microbiota. 40 Further investigations comparing pretreatment with antibiotics before FMT improve clinical outcomes in active UC are currently underway.
Follow-up and Endpoints
Both short-term safety endpoints and long-term follow-up are needed to better assess predictors of clinical efficacy, safety, and identify possible translational markers to inform a mechanisms to explain FMT's efficacy including potentially short chain fatty acid production. [40] [41] [42] [43] Ponsieon et al followed patients with UC for up to 3 years post-FMT, and identified enhancement of Clostridium clusters IV and XIVa post-transplant as predictive of sustained response. 25 Exploring bacterial dynamics and transkingdom relationships will be important to yield deeper mechanistic insights. Furthermore, such foundational knowledge may help to guide development of future innovations, such as anaerobic delivery of full microbial communities or selective enhancement of key micobes, which could lead to defined, rationally selected microbiome-based therapeutics.
The proliferation of research on FMT use in patients with IBD over the past few years has provided exciting evidence supporting the use of this novel intervention and highlighting the potential for development new microbial therapies to treat IBD. Looking forward, these active trials as well as additional clinical work built upon the foundations highlighted in this review may begin to provide answers to the many open questions in the field and could ultimately help us understand where FMT should be positioned within the IBD treatment paradigm. 
